BRIEF REPORTArecoline via Miniosmotic Pump Improves AF64A-Impaired Radial Maze Performance in Rats: A Possible Model of Alzheimer's Disease☆,☆☆,★
References (29)
- et al.
Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease
Clinical Pharmacology and Therapeutics
(1996) - et al.
Acute and chronic arecoline: Effects on a scopolamine-induced deficit in complex maze learning
Pharmacology, Biochemistry and Behavior
(1996) - et al.
AF64A-induced working memory impairment: Behavioral, neurochemical and histological correlates
Brain Research
(1988) - et al.
Hemicholinium-3 prevents the working memory impairments and the cholinergic hypofunction induced by ethylcholine aziridinium ion (AF64A)
Brain Research
(1989) - et al.
Reversible cholinergic changes induced by AF64A in rat hippocampus and possible septal compensatory effects
Neuropharmacology
(1992) - et al.
(±)-cis-2-Methyl-spiro(1,3-oxathiolane-5,3′) quninuclide (AF102B): A new M1
Neuroscience Letters
(1989) - et al.
M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update
Annals of the New York Academy of Sciences
(1996) - et al.
Ethylcholine aziridinium (AF64A; ECMA) and other potential cholinergic neuron-specific neurotoxins
Psychopharmacology: The third generation of progress
(1987) - et al.
Impaired phosphoinositide hydrolysis in Alzheimer's disease brain
Neurobiology of Aging
(1994) - et al.
Regional alterations in M1 muscarinic receptor-G protein coupling in Alzheimer's disease
Journal of Neuropathology and Experimental Neurology
(1995)
Intracerebroventricular administration of ethylcholine mustard aziridinium ion (AF64A) reduces release of acetylcholine from rat hippocampal slices
Neuropharmacology
Time course of ethylcholine aziridinium ion (AF64A)-induced cholinotoxicity in vitro
Neuropharmacology
Cognitive test performance in detecting, staging and tracking Alzheimer's disease
Archives of Neurology
Protein measurement with the folin phenol reagent
Journal of Biological Chemistry
Cited by (14)
Prevention of precipitated withdrawal symptoms by activating central cholinergic systems during a dependence-producing schedule of morphine in rats
2000, Brain ResearchCitation Excerpt :In fact, the DFP regimen we used had already reduced brain levels of AChE to only 13% of control enzyme activity just prior to the initiation of withdrawal. The dose we chose for arecoline was based upon those shown to improve memory in behavioral tasks performed by rats [5, 28]. This insured that arecoline, as we employed it, was compatible with higher cognitive activities, and therefore, unlikely to induce untoward reactions in the animals.
5HT antagonists attenuate MK801-impaired radial arm maze performance in rats
1999, Neurobiology of Learning and MemoryEffects of aqueous extracts of "betel quid" and its constituents on testosterone production by dispersed mouse interstitial cells
2004, American Journal of Chinese MedicineBetel quid health risks of insulin resistance diseases in poor young south Asian native and immigrant populations
2020, International Journal of Environmental Research and Public HealthTrue alignment of preclinical and clinical research to enhance success in CNS drug development: A review of the current evidence
2016, Journal of PsychopharmacologySynthesis and acetylcholinesterase/butyrylcholinesterase inhibition activity of arecoline-, 4-thiazolidinone- and piperidine- based conjugates
2015, Asian Journal of Pharmaceutical and Clinical Research
- ☆
The authors thank Dr. Gary Wenk and Dr. Robert Stackman for their technical advice on establishing the choline acetyltransferase assay. Thanks are also extended to Cathy Hoffman, Stephanie Maurer, and Fran Storch for their assistance in maze training, surgeries, maze testing, and brain harvesting. Thanks are extended to Mike Weaver, Charlie Vorhees, and Ed Godfrey for their work in building and maintaining the radial maze and to Bob LaForge for his work in generating the computer program and electronic interfaces which track and record maze activity. The authors thank Dr. Frank Shen and Tammy Coffey for their statistical analysis of the data. Finally, thanks are extended to Erica DiPaola for her work in preparing this manuscript.
- ☆☆
Address reprint requests to Carl Boast, Ph.D., CNS Disorders Division, Wyeth-Ayerst Research, CN 8000, Princeton, NJ 08543-8000.
- ★
H. Y. Meltzer, Ed.